Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

André W Broekmans

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|May 22, 2014
[The new pharmacovigilance legislation in practice]André W Broekmans, Peter G M Mol
Schizophrenia Bulletin|April 16, 2003
Amisulpride: is there a treatment for negative symptoms in schizophrenia patients?Jitschak G Storosum, André J A Elferink, Barbara J van Zwieten, et al.
Drug Safety|January 1, 2016
Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR ReportsKevin Klein, Joep H G Scholl, Niels S Vermeer, et al.
Clinical Pharmacology and Therapeutics|June 15, 2018
Medicines Adaptive Pathways to Patients: Why, When, and How to Engage?Hans-Georg Eichler, Nicola Bedlington, Mathieu Boudes, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Nederlands Tijdschrift Voor Geneeskunde|May 22, 2014
[The new pharmacovigilance legislation in practice]André W Broekmans, Peter G M Mol
Schizophrenia Bulletin|April 16, 2003
Amisulpride: is there a treatment for negative symptoms in schizophrenia patients?Jitschak G Storosum, André J A Elferink, Barbara J van Zwieten, et al.
Drug Safety|January 1, 2016
Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR ReportsKevin Klein, Joep H G Scholl, Niels S Vermeer, et al.
Clinical Pharmacology and Therapeutics|June 15, 2018
Medicines Adaptive Pathways to Patients: Why, When, and How to Engage?Hans-Georg Eichler, Nicola Bedlington, Mathieu Boudes, et al.
Pageof 1